This piece cuts through the noise of pharmaceutical innovation to expose a quiet, trillion-dollar failure: the market's inability to test drugs that are already safe but lack a patent. Nicholas Reville, the Executive Director and cofounder of the Center for Addiction Science, Policy, and Research, argues that the gap isn't a lack of scientific curiosity, but a structural economic flaw where the private sector has zero incentive to run definitive trials on off-patent medications and dietary supplements. The urgency here is financial as much as it is medical; we are paying hundreds of billions annually for fragmented data while potentially superior, low-cost treatments sit on the shelf, unproven and inaccessible.
The Economics of the Trial Gap
Reville identifies a stark reality in how the pharmaceutical industry operates. While companies rush to patent new compounds, they abandon the testing of existing ones once exclusivity expires. "For drugs and therapies on patent, a patent holder has a strong interest in running randomized evaluations and navigating the drug through the FDA's approval process," Reville writes. "By contrast, for drugs and therapies with no patent holder, no one has much interest in funding expensive randomized trials or working assiduously to move through the FDA regulatory process for rapid approval (or even slow approval)."
This market failure leaves patients with expensive, branded options while cheaper, generic alternatives remain unverified for new uses. The author points out that Americans spend roughly $70 billion a year on supplements, often based on thin or contradictory evidence. Meanwhile, the loss of patent protection leads to a "near-total cessation of clinical trials for new indications," creating what Reville calls a "repurposing cliff." The result is a staggering social cost, estimated at several trillion dollars in lost opportunities, where patients are denied access to treatments that could be both safer and more affordable.
Critics might argue that shifting the burden of trials to the National Institutes of Health (NIH) creates a moral hazard, potentially encouraging companies to abandon their own research responsibilities. However, Reville's framing suggests this is not a shift of responsibility but a filling of a void that the market cannot and will not fill on its own.
The market fails because these trials are very expensive, and even if the trial is successful and the company gets a 3-year indication-specific labelling exclusivity from the FDA, they cannot prevent other generic versions of the drug from being prescribed off-label for this new indication, which kills their potential profits.
A Blueprint for High-Leverage Action
To solve this, Reville proposes the creation of an NIH High-Leverage Trials (HILT) Program. This isn't just about funding more research; it's about building a dedicated operational engine to run large-scale, definitive Phase III trials for off-patent drugs and supplements. The proposal draws on the success of the Best Pharmaceuticals for Children Act (BPCA), where the NIH successfully navigated trials for pediatric uses of existing drugs. "HILT would function as a funding, research, and regulatory advancement body," Reville explains, aiming to generate "gold standard" evidence that can drive coverage decisions by Medicare and private payers.
The program would not merely publish papers; it would act as a non-commercial sponsor to navigate the FDA, ensuring that positive results translate into label changes and patient access. By focusing on compounds with extensive safety histories, HILT could run trials at a fraction of the cost of traditional drug development. The author highlights that "loss of exclusivity for a medicine leads to a near-total cessation of clinical trials for new indications, due to the collapse of private incentives," making government intervention the only viable path to unlocking these treatments.
Transforming Safety and Cost
The implications for public safety are profound. Currently, dietary supplements are lightly regulated, leading to thousands of emergency department visits annually. Reville argues that HILT would not promote supplements but would provide the transparent, high-quality evidence needed to guide the public. "Large-scale safety and efficacy trials on supplements will help guide the public towards safer and more effective supplements and clarify effective dose levels," he notes. This approach moves beyond the binary of "safe vs. dangerous" to a nuanced understanding of dosing, quality, and specific indications.
The economic argument is equally compelling. Reville cites the National Eye Institute's Comparison of AMD Treatments Trials (CATT), which compared a $2,000 drug against a $50 alternative. The trial showed they were equally effective, saving Medicare an estimated $40 billion. "This is the type of head-to-head comparison that no commercial player had an incentive to run," Reville writes. By replicating this model, HILT could generate savings that pay for the program many times over, shifting the healthcare system toward cost-effective, evidence-based care.
Modernizing Trial Design
A key strength of the proposal is its focus on operational innovation. Reville suggests that HILT could leverage modern trial designs that the risk-averse pharmaceutical industry avoids. These include embedded electronic health record trials, decentralized telehealth models, and multi-arm platform trials. "Pharma is much more likely to pursue lower cost trial innovations at Phase III if precedents are demonstrated," Reville observes. By acting as a pioneer, the NIH could establish new standards for efficiency, using real-world data and remote monitoring to slash costs without sacrificing rigor.
The proposal outlines several legislative pathways to establish HILT, from expanding the BPCA to creating a new NIH center. The core mission remains consistent: align evidence generation with payer coverage to ensure that when a treatment is proven effective, it is actually available to patients. "The goal should be to achieve patient access and coverage, not simply publish evidence," Reville stresses.
HILT would not increase or alter regulatory burdens on the private sector. Instead, it fills a void that the industry is not able to address, providing cost savings and better treatments to all Americans.
Bottom Line
Reville's argument is a compelling call to fix a broken incentive structure that leaves billions in potential savings and millions of patients without access to proven, low-cost treatments. The strongest part of the proposal is its pragmatic focus on operational efficiency and payer alignment, moving beyond mere data collection to actual market transformation. However, the biggest vulnerability lies in the political will required to establish a permanent, well-funded program within the NIH, especially when the immediate beneficiaries are diffuse and the savings accrue to payers rather than the program itself. The next step for readers to watch is whether this specific legislative framework gains traction in Congress as a bipartisan solution to rising healthcare costs.